Online inquiry

IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ10217MR)

This product GTTS-WQ10217MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets RHD gene. The antibody can be applied in prevention of feto-maternal allo-immunization in RhD- women research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_001127691.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	6007
UniProt ID	Q02161

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10217MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ15681MR	IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	VB6-845
GTTS-WQ13899MR	IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	REGN-2176
GTTS-WQ12994MR	IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	PEG sTNF-RI
GTTS-WQ8465MR	IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	HTI-1088
GTTS-WQ10427MR	IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))	mRNA	LY-2495655
GTTS-WQ2629MR	IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	AMG 592
GTTS-WQ12944MR	IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	PankoMab
GTTS-WQ1318MR	IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	ABT-700

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST